Abstracts tagged "immunology"

Abstract Number: 1657 • ACR Convergence 2024
Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis
Marie Binvignat¹, Maria Marco-Salvador¹, Johanna Dubois¹, Paul Stys¹, Alice Courties², Fabien Pitoiset¹, Alexandra Roux³, Michele Barbier⁴, Roberta Lorenzon², Signe Hassler³, Claire Ribet¹, helene Vantomme¹, Leslie Adda¹, Vanessa Mhanna¹, Nicolas Coatnoan², Gwladys Fourcade¹, Vimala Didelot¹, PIerre Barennes¹, Lise Minssen², Caroline Aheng¹, Sanchita Bhattacharya⁵, Yannick Marie⁶, Atul J. butte⁵, Adrien Six¹, Nicolas Tchitcheck¹, Michelle Rosenzwajg¹, Francis Berenbaum¹, David Klatzmann¹, Encarnita Mariotti-Ferrandiz¹ and Jérémie Sellam⁷, ¹Sorbonne University, Paris, France, ²AP-HP, Paris, France, ³Sorbonne University, Paris, ⁴AP-HP, Paris, ⁵UCSF, San Francisco, ⁶ICM, Paris, France, ⁷Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France
Background/Purpose: Pain is the main osteoarthritis (OA) symptom and remains poorly understood. While significant attention has been given to the potential role of innate immunity,…
Abstract Number: 1857 • ACR Convergence 2024
Thymic Mimetic Cells in Humans, Mice and Fish Are Evolutionarily Ancient with Species-specific Adaptations
Brooke Huisman¹, Daniel Michelson¹, Sara Rubin¹, Katherine Kohlsaat², Wilson Gomarga², Yuan Fang¹, Ji Myung Lee², Pedro del Nido², Meena Nathan², Christophe Benoist¹, Leonard Zon² and Diane Mathis¹, ¹Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Boston, MA
Background/Purpose: Thymic mimetic cells are molecular hybrids between medullary thymic epithelial cells (mTECs) and diverse peripheral cell types. They are involved in eliminating autoreactive T…
Abstract Number: 2217 • ACR Convergence 2024
A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
Gilad Halpert¹, Eri Govrin², Boris Gilburd³, Shlomo Segev³, Omer Gendelman⁴, Abdulla Watad⁵, Yehuda Shoenfeld⁶, David Meiri⁷ and Howard Amital⁸, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Sdot Micha, Israel, ³Sheba Medical Center, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶sheba medical center , Israel, Ramat Gan, Israel, ⁷Technion-Israel Institute of Technology, Haifa, Israel, ⁸Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…
Abstract Number: 2686 • ACR Convergence 2024
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
David Fox¹, Laura Cooney², Lia Stelzig³, Robert Lafyatis⁴, Johann Gudjonsson⁵, Lam Tsoi⁶, Maureen Mayes⁷, Ankoor Shah⁸, Suzanne Kafaja⁹, William Barry³, Ellen Goldmuntz¹⁰, Dawn Smilek¹¹ and Dinesh Khanna⁶, ¹University of Michigan, Dexter, MI, ²University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ³Rho, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, MI, ⁷UTHealth Houston Division of Rheumatology, Houston, TX, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ¹⁰Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, ¹¹Immune Tolerance Network, UCSF, San Francisco, CA
Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
Abstract Number: 0060 • ACR Convergence 2024
Spectral Cytometry Shows Increased CD56hi NK Cells and New HLA-DR+CD56+ Phenotypes in RA
Estelle Khairallah¹, Haani Qudsi², Jihad Ben Gabr¹, Andras Perl³ and Christian Geier¹, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Previous studies of RA patients have shown changes in NK cell populations (as defined by CD56 expression). The nature of these cellular changes remains…
Abstract Number: 0875 • ACR Convergence 2024
Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations
Daniel Patton, Alex Chen, Justin Bowser, Kaelen Encarnacion, Jennifer Gardell, Emily Gilbertson, Susan Julien, Meghan Maurer, Brent Meengs, Nadine Morgan, Allison O'Rourke, Cong Tan, Jon Therriault, Kristine Swiderek and Courtney Crane, Mozart Therapeutics, Seattle, WA
Background/Purpose: CD8 Treg, characterized in human peripheral blood mononuclear cells (PBMC) by expression of inhibitory killer immunoglobulin receptors (KIRs), regulate immune balance by eliminating self-reactive…
Abstract Number: 1725 • ACR Convergence 2024
Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering significant benefits in various malignancies. However, these therapies can induce immune-related adverse events (irAEs), including…
Abstract Number: 1862 • ACR Convergence 2024
Folate Receptor β CAR-Tregs Induce Monocyte Apoptosis and Immune Polarization: Potential for Therapeutic Application in Rheumatoid Arthritis
Xiangni Wu¹, Pin-I Chen², Magdiel Pérez Cruz³, Kent Jensen³ and Everett Meyer³, ¹UMKC, KANSAS CITY, MO, ²Department of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, USA., Sunnyvale, CA, ³Department of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, USA., Stanford
Background/Purpose: Rheumatoid arthritis (RA) affects approximately 1.3 million adults in the United States, causing significant morbidity and economic burden. Current treatments reduce inflammation and slow…
Abstract Number: 2348 • ACR Convergence 2024
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
Diamant Thaçi¹, Luis Puig², Joseph F. Merola³, Denis Jullien⁴, Antonio Costanzo⁵, Maggie Wang⁶, Delphine Deherder⁷, José M. López Pinto⁸ and Mark Lebwohl⁹, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ²Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ³UT Southwestern Medical Center, Dallas, TX, ⁴Department of Dermatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France, ⁵Department of Dermatology, Humanitas Clinical and Research Centre, IRCCS, Rozzano, Milan, Italy, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Braine-l'Alleud, Belgium, ⁸UCB Pharma, Madrid, Spain, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Clinical improvements through Week 152, with no unexpected safety findings, were previously reported with bimekizumab (BKZ) in the BE SURE phase 3 trial and…
Abstract Number: 0078 • ACR Convergence 2024
Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity
Archita Srinath¹, Daniele Mauro², Mariia Korshko³, Shaghayegh Foroozan⁴, Mansi Aparnathi⁵, Francesco Ciccia⁶ and Nigil Haroon⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Campania, Italy, Naples, Naples, Italy, ³University Health Network, Toronto, ON, Canada, ⁴University Health Network/University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Toronto, Canada, ⁶University of Campania, Naples, Italy, ⁷Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however, over 40% of patients do…
Abstract Number: 0891 • ACR Convergence 2024
Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells
Jacquelyn Nestor¹, Rachelly Normand¹, Wamia Said¹, Sergio Aguilar², Nandini Samanta¹, Sidney Martin¹, Roya Best¹, Hoang Anh Tran¹, Adrien Antoinette¹, Eilish Dillon³, Devin King³, April Jorge⁴, Maureen Leonard⁴, Pritha Sen³, Kerry Reynolds⁴, John Stone⁵, Michelle Rengarajan¹, Tanuja Chitnis⁶, Kevin Wei⁷, Deepak Rao³, Andrew Luster⁸, Gary Reynolds¹ and Alexandra-Chloe Villani¹, ¹Massachusetts General Hospital, Harvard Medical School, Broad Institute of MIT and Harvard, Boston, MA, ²National Center for Genomic Analysis, Barcelona, Spain, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸Massachusetts General Hospital, Charlestown, MA
Background/Purpose: Rheumatologic diseases are characterized by distinct clinical presentations and patterns of organ involvement, yet share many genetic risk factors and treatment responses. This suggests…
Abstract Number: 1730 • ACR Convergence 2024
Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors
Daniel Portnoy¹, Matthieu J Piola², Luke Hao², Robert Winchester², Adam Mor² and Yevgeniya Gartshteyn³, ¹Columbia University Irving Medical Center, New Yok, NY, ²Columbia University Irving Medical Center, New York, NY, ³Columbia University Irving School of Medicine, New York, NY
Background/Purpose: Inflammatory arthritis is one of the most common immune-related adverse events (irAEs) resulting from immune checkpoint inhibitors (ICIs). We hypothesized that T cells present…
Abstract Number: 1867 • ACR Convergence 2024
RNA Polymerase III Specific CD8+ T Cells at the Interface Between Scleroderma and Cancer
Eleni Tiniakou¹, Mekha Thomas², Ami Shah³, Fredrick Wigley⁴, Livia Casciola-Rosen², Kellie Smith², Antony Rosen² and Erika Darrah², ¹Johns Hopkins University, Lutherville Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD
Background/Purpose: Increasing evidence suggests an immunologic link between cancer and autoimmunity. Systemic sclerosis (SSc), offers a unique opportunity to study the evolution of naturally occurring…
Abstract Number: 2386 • ACR Convergence 2024
Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity
Alexandra Reese¹, Chandana Keshavamurthy², Sneha Centala¹, Samantha Ahrens¹, Shivani Shah², Douglas Reeves², William Davis³, Robert Quinet⁴, Jerald Zakem¹, Qingli Wu¹, Kimmy Tran¹, Teresa Leeth⁵, Daniyal Nadeem⁶, Sarwat Umer⁷, Samina Hayat⁵ and Xin Zhang¹, ¹Ochsner Health, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health, River Ridge, LA, ⁵Louisiana State University Shreveport, Shreveport, LA, ⁶LSU Shreveport, Shreveport, ⁷LSU HEALTH SHREVEPORT, SHREVEPORT, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by autoantibodies and disruption of multiple organs due to immunomodulatory dysfunction. Obesity is a…
Abstract Number: 0082 • ACR Convergence 2024
Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis
Mark Harland¹, Paula David², Chi Wong¹, Jake Weddell¹, Abhay Rao³, Almas Khan³, Jake Timothy³, Peter Loughenbury³, Robert Dunsmuir³, Vishal Borse³, Campbell MacEachern³, Antonius Pieter Van der Heuvel⁴, Warner Chen⁴, Tom Macleod¹ and Dennis McGonagle⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel, Ramat Gan, Israel, ³Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, USA, Spring House, PA, ⁵National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: Both peripheral and axial spondyloarthropathy (SpA), psoriasis and inflammatory bowel disease are strongly linked to IL-23 pathway immunogenetics and immunology. Unexpectedly, IL-23 inhibition lacked…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].